Adipocyte Differentiation,Mitochondrial Gene Expression and Fat Distribution: Differences between Zidovudine and Tenofovir after 6 Months

Abstract

Background

Abnormal lipid metabolism and cell oxidative mechanisms are reported in patients on antiretroviral treatment. We compared the expression of several key adipocyte genes in HIV-infected patients randomized to antiretroviral regimens containing zidovudine (AZT) or tenofovir disoproxil fumarate (TDF).

Methods

Subcutaneous fat was sampled from 32 HIV-positive treatment-naive patients before and 6 months after randomization to AZT/lamivudine/efavirenz (n=15) or TDF/emtricitabine/efavirenz (n=17) plus 15 HIV-negative matched controls. Expression of genes involved in adipocyte differentiation, lipid metabolism, mitochondrial function and glucocorticoid generation were pro-filed using real-time PCR. Lipoprotein lipase and hepatic lipase activity were assessed.

Results

Before treatment, 11β-hydroxysteroid dehydrogenase expression was down-regulated compared with controls. Following 6 months treatment with AZT, there was a significant increase in visceral adipose tissue (VAT; P=0.02) and the ratio of VAT to subcutaneous adipose tissue (P=0.008), down-regulation of cytochrome B (P=0.003) and cytochrome oxidase (COX)-3 gene expression (P=0.03), up-regulation of NADH dehydrogenase (P=0.008) and nuclear-encoded COX-4 (complex IV) gene expression (P=0.012). Genes involved with adipocyte cortisol generation, fatty acid metabolism and the tricarboxylic acid cycle were up-regulated. In the TDF-treated patients, there was no significant change in regional body fat or mitochondrial genes compared with pretreatment values. Changes in the expression of genes involved with cortisol and fatty acid metabolism were less marked with TDF.

Conclusions

Interference with the mitochondrial electron transport chain appears to occur early in an AZT- containing regimen and occurs at a time when there is increased visceral fat and up-regulation of genes involved with adipocyte differentiation and fatty acid flux.

References

Carr

HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.

AIDS 2003; 17 Suppl 1: S141–S148.

Gougeon

M.L.

, Penicaud

, Fromenty

, Leclercq

, Viard

J.P.

, Capeau

Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.

Antivir Ther 2004; 9: 161–177.

Brown

T.T.

Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.

AIDS 2005; 19: 1375–1383.

Lichtenstein

K.A.M.

Redefining lipodystrophy syndrome: risks and impact on clinical decision making.

J Acquir Immune Defic Syndr 2005; 39: 395–400.

Shlay

J.C.M.

Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.

J Acquir Immune Defic Syndr 2008; 48: 53–62.

Arribas

J.R.M.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

J Acquir Immune Defic Syndr 2008; 47: 74–78.

Brinkman

, Smeitink

, Romijn

, Reiss

Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy related lipodystrophy.

Lancet 1999; 354: 1112–1115.

Pace

C.S.

, Martin

A.M.

, Hammond

E.L.

, Mamotte

C.D.

, Nolan

D.A.

, Mallal

S.A.

Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.

Antivir Ther 2003; 8: 323–331.

Villarroya

, Domingo

, Giralt

Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity.

Trends Pharmacol Sci 2005; 26: 88–93.

10.

Matthews

D.R.

, Hosker

J.P.

, Rudenski

A.S.

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Diabetologia 1985; 28: 412–419.

11.

Tomlinson

J.W.

, Walker

E.A.

, Bujalska

I.J.

11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.

Endocr Rev 2004; 25: 831–866.

12.

Lavery

G.G.

, Walker

E.A.

, Draper

Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation.

J Biol Chem 2006; 281: 6546–6551.

13.

McComsey

G.A.

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.

AIDS 2005; 19: 15–23.

14.

Spiegelman

B.M.

, Puigserver

, Wu

Regulation of adipogenesis and energy balance by PPARgamma and PGC-1.

Int J Obes Relat Metab Disord 2000; 24 Suppl 4: S8–S10.

15.

Scarpulla

R.C.

Nuclear control of respiratory gene expression in mammalian cells.

J Cell Biochem 2006; 97: 673–683.

16.

Cannino

, Di Liegro

C.M.

, Rinaldi

A.M.

Nuclear-mitochondrial interaction.

Mitochondrion 2007; 7: 359–366.

17.

Zambon

, Hashimoto

S.I.

, Brunzell

J.D.

Analysis of techniques to obtain plasma for measurement of levels of free fatty acids.

J Lipid Res 1993; 34: 1021–1028.

18.

Hammond

, Nolan

, McKinnon

, Pace

, Mallal

Assessing the contribution of ART, HIV and host factors to adipocyte tissue changes occurring in HIV-infected individuals: risk profile for lipoatrophy.

Antivir Ther 2005; 10: L4.

19.

Abu-Elheiga

, Matzuk

M.M.

, Abo-Hashema

K.A.

, Wakil

S.J.

Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2.

Science 2001; 291: 2613–2616.

20.

Adams

, Montague

C.T.

, Prins

J.B.

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

J Clin Invest 1997; 100: 3149–3153.

21.

Bujalska

I.J.

, Kumar

, Hewison

Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase.

Endocrinology 1999; 140: 3188–3196.

22.

Hauner

, Schmid

, Pfeiffer

E.F.

Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells.

J Clin Endocrinol Metab 1987; 64: 832–835.

23.

Mallon

P.W.

, Miller

, Cooper

D.A.

, Carr

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.

AIDS 2003; 17: 971–979.

24.

Kratz

, Purnell

J.Q.

, Breen

P.A.

Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy.

J Clin Endocrinol Metab 2008; 93: 959–966.

25.

Kim

M.J.

, Leclercq

, Lanoy

A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study.

Antivir Ther 2007; 12: 1273–1283.

26.

Caron

, Auclairt

, Vissian

Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues.

Antivir Ther 2008; 13: 27–38.

27.

Rousset

, Alves-Guerra

M.C.

, Mozo

The biology of mitochondrial uncoupling proteins.

Diabetes 2004; 53 Suppl 1: S130–S135.

28.

Lenaz

, Baracca

, Carelli

Bioenergetics of mitochondrial diseases associated with mtDNA mutations.

Biochim Biophys Acta 2004; 1658: 89–94.

29.

Nerurkar

P.V.

, Shikuma

C.M.

, Nerurkar

V.R.

Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy.

Clin Biochem 2001; 34: 519–529.

30.

Kosmiski

L.A.

, Kuritzkes

D.R.

, Sharp

T.A.

Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.

Metabolism 2003; 52: 620–625.

31.

Mallon

P.W.G.

, Unemori

, Sedwell

In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.

J Infect Dis 2005; 191: 1686–1696.

32.

Grunfeld

, Pang

, Doerrler

, Shigenaga

, Jensen

, Feingold

Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

J Clin Endocrinol Metab 1992; 74: 1045–1052.

33.

Eckel

R.H.

Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases.

N Engl J Med 1989; 320: 1060–1068.

34.

Shahmanesh

, Das

, Stolinski

Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.

J Clin Endocrinol Metab 2005; 90: 755–760.

35.

Umpleby

A.M.

, Das

, Stolinski

Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy.

Antivir Ther 2005; 10: 663–670.

36.

Yang

W.S.

, Lee

W.J.

, Funahashi

Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin.

J Clin Endocrinol Metab 2001; 86: 3815–3819. [erratum appears in J Clin Endocrinol Metab 2002; 87: 1626].

37.

Das

, Shahmanesh

, Stolinski

In treatment naive and antiretroviral treated HIV infected subjects reduced plasma adiponectin is associated with a reduced fractional catabolic rate of VLDL, IDL and LDL apolipoprotein B-100.

Diabetologia 2006; 49: 538–542.

38.

Zaera

M.G.

, Miro

, Pedrol

Mitochondrial involvement in antiretroviral therapy-related lipodystrophy.

AIDS 2001; 15: 1643–1651.

39.

Cote

H.C.

, Brumme

Z.L.

, Craib

K.J.

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

N Engl J Med 2002; 346: 811–820.

40.

Miro

, Lopez

, Martinez

Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals.

Clin Infect Dis 2004; 39: 710–716.

41.

Kannisto

, Sutinen

, Korsheninnikova

Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy.

AIDS 2003; 17: 1753–1762.

42.

Viengchareun

, Caron

, Auclair

Mitochondrial toxicity of indinavir, stavudine and zidovidine involves multiple cellular targets in white and brown adipocytes.

Antivir Ther 2007; 12: 919–929.

43.

Birkus

, Hitchcock

M.J.

, Cihlar

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

Antimicrob Agents Chemother 2002; 46: 716–723.

44.

Cherry

C.L.

Exposure to dideoxynucleosides is refected in lowered mitochondrial DNA in subcutaneous fat.

J Acquir Immune Defic Syndr 2002; 30: 271–277.

45.

Giralt

, Domingo

, Guallar

J.P.

HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy.

Antivir Ther 2006; 11: 729–740.

46.

Hammond

, Nolan

, James

, Metcalf

, Mallal

Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy.

AIDS 2004; 18: 815–817.

47.

Miro

, Lopez

, Pedrol

Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy.

Antivir Ther 2003; 8: 333–338.

48.

Kosmiski

L.A.

, Bacchetti

, Kotler

D.P.

Relationship of fat distribution with adipokines in human immunodeficiency virus infection.

J Clin Endocrinol Metab 2008; 93: 216–224.

49.

Tomlinson

J.W.

, Stewart

P.M.

Modulation of glucocorticoid action and the treatment of type-2 diabetes.

Best Pract Res Clin Endocrinol Metab 2007; 21: 607–619.

50.

Sutinen

, Kannisto

, Korsheninnikova

In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue.

Diabetologia 2004; 47: 1668–1671.

51.

Jacobson

D.L.

, Tang

A.M.

, Spiegelman

Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey).

J Acquir Immune Defic Syndr 2006; 43: 458–466.

52.

Wand

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

AIDS 2007; 21: 2445–2453.